Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol.

Authors:
Vignan Yogendrakumar
Vignan Yogendrakumar
University of British Columbia
Canada
Dean Fergusson
Dean Fergusson
University of Ottawa
Canada
Dar Dowlatshahi
Dar Dowlatshahi
University of Ottawa
Canada

Syst Rev 2019 Apr 18;8(1):99. Epub 2019 Apr 18.

Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, 1053 Carling Avenue, Ottawa, ON, K1Y 4E9, Canada.

Background And Purpose: Cerebral venous thrombosis causes disability from venous infarct and hemorrhage and potential mortality. Anticoagulation improves survival and disability outcomes, yet direct oral anticoagulants are currently not indicated in cerebral venous thrombosis due to lack of evidence, despite being on the market for nearly a decade. This systematic review will collate evidence of reported safety and efficacy of direct oral anticoagulant therapy in cerebral venous thrombosis.

Methods: A search strategy was developed with a research librarian and registered on a protocol database (PROSPERO CRD42017078398). All published studies from MEDLINE and EMBASE up to February 2019 containing patients diagnosed with cerebral venous thrombosis who were treated with a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) will be included. A risk of bias analysis will be performed to evaluate quality of studies overall.

Discussion: Current guidelines in the treatment of cerebral vein thrombosis dating back to 2011 from the American Heart Association/American Stroke Association endorse the utility of anticoagulation for the treatment of cerebral vein thrombosis; however, they did not support the use of direct oral anticoagulants. Updated guidelines from the European Stroke Organization, endorsed by the European Academy of Neurology in 2017, also refute utilization of direct oral anticoagulants due to a lack of evidence. There have been nearly 10 years of experience with direct oral anticoagulants in the treatment of venous thrombosis and prevention of stroke in patients with atrial fibrillation, with purported efficacy and safety in comparison with heparins and vitamin K antagonists. Our goal is to undertake a systematic review to assess the effectiveness and safety of direct oral anticoagulants in patients with cerebral vein thrombosis to help guide clinical decision-making for patients unable to take heparins or vitamin K antagonists and to direct future studies to contribute further to an area of certain evidence-based needs.

Systematic Review Registration: PROSPERO CRD42017078398.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13643-019-1022-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474061PMC
April 2019
1 Read

Publication Analysis

Top Keywords

direct oral
32
oral anticoagulants
24
cerebral venous
20
venous thrombosis
20
treatment cerebral
12
systematic review
12
cerebral vein
12
vein thrombosis
12
direct
9
heparins vitamin
8
vitamin antagonists
8
oral anticoagulant
8
prospero crd42017078398
8
lack evidence
8
thrombosis
8
anticoagulants treatment
8
cerebral
8
venous
7
oral
7
anticoagulants
6

References

(Supplied by CrossRef)
Article in Stroke.
JM Ferro et al.
Stroke. 2004
Article in Lancet.
KM Einhäupl et al.
Lancet. 1991
Article in Cochrane Database Syst Rev
J Coutinho et al.
Cochrane Database Syst Rev 2011
Article in Stroke.
G Saposnik et al.
Stroke. 2011
Article in Eur J Neurol
JM Ferro et al.
Eur J Neurol 2017
Article in N Engl J Med.
S Schulman et al.
N Engl J Med. 2009
Article in Ther Clin Risk Manag
YH Mekaj et al.
Ther Clin Risk Manag 2015
Article in Syst Rev
D Moher et al.
Syst Rev 2015
Article in BMJ
A Liberati et al.
BMJ 2009
Article in BMJ
JA Sterne et al.
BMJ 2016
Article in Stroke.
C Geisbüsch et al.
Stroke. 2014

Similar Publications